Findings

What do systematic reviews say?

3 questions · 4 findings · 3 reviews · asked by two or more reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 25%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 50%Moderate 1 · 25%High 0 · 0%

Short‐acting insulin analogues vs regular human insulin

All‐cause mortality

Short‐acting insulin analogues showed no clear difference in all‐cause mortality (N) compared with regular human insulin (moderate certainty).

2 findings from 2 reviews · compare the 2 reviews

Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
Peto OR 1.66 [0.41, 6.64]
6 studies · 2519 participants
Moderate
Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: insulin detemir vs NPH insulin

All‐cause mortality

Insulin detemir showed no clear difference in all‐cause mortality compared with NPH insulin (low certainty).

1 finding from 1 review · compare the 2 reviews

(Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
Peto OR 0.74 [0.2, 2.65]
8 studies · 2328 participants
Low

Insulin glargine vs NPH insulin

All‐cause mortality

Insulin glargine showed no clear difference in all‐cause mortality compared with NPH insulin (low certainty).

1 finding from 1 review · compare the 2 reviews

(Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
Peto OR 1.06 [0.62, 1.82]
14 studies · 6173 participants
Low